ReviewThe pharmacogenomics journal2004
The pharmacogenomics of selective serotonin reuptake inhibitors.
Review in The pharmacogenomics journal, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients.Molecular psychiatry · 2007Pooled it
- Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2016Trial
- Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.British journal of clinical pharmacology · 2014Trial
- Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.The pharmacogenomics journal · 2012Trial
- Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.Clinical pharmacology and therapeutics · 2011Trial
- scRank infers drug-responsive cell types from untreated scRNA-seq data using a target-perturbed gene regulatory network.Cell reports. Medicine · 2024Article
- Pharmacogenomic profile of a central European urban random population-Czech population.PloS one · 2023Observational
- Blood-based biomarkers predicting response to antidepressants.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
- Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype.ACS chemical neuroscience · 2014Article
- Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.The pharmacogenomics journal · 2013Article
- Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder.Iranian journal of psychiatry · 2013Article
- Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.Neuromolecular medicine · 2010Article
- Selective serotonin reuptake inhibitors pathway.Pharmacogenetics and genomics · 2009Article
- Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 variations does not impact alcohol dependence disorder features.International journal of environmental research and public health · 2009Article
- SLC6A4 variation and citalopram response.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2009Article
- Polymorphic Variations in 5-HT2A, 5-HTT and DISC 1 in First Episode Schizophrenia Patients.EJIFCC · 2009Article
- Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders.Pharmacogenomics and personalized medicine · 2008Article
- Brief report: aggression and stereotypic behavior in males with fragile X syndrome--moderating secondary genes in a "single gene" disorder.Journal of autism and developmental disorders · 2008Article
- Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey.Molecular biology reports · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of selective serotonin (5-HT) reuptake inhibitors (SSRIs) has significantly improved the pharmacological treatment of a range of psychiatric disorders. Nevertheless, despite the undoubted advantages of antidepressant treatment in terms of improved tolerability to therapy while maintaining a high level of efficacy, not all patients benefit from it; an appreciable proportion do not respond adequately, while others may show adverse reactions. The necessary change of the initial treatment choice often requires extended periods for the remission of symptomatology. Such difficulties could be avoided if it should be possible to determine more quickly the most suitable drug. Several factors have been thought to influence the outcome of antidepressant therapy. Among the factors influencing the interindividual variability in response to treatment with SSRI, differences in genetic features may play a significant role. Several genetic polymorphisms have been associated with therapeutic SSRI response, including genetic variants of the 5-HT transporter, 5-HT-2A-receptor, tryptophan hydroxylase, brain-derived neurotrophic factor, G-protein beta3 subunit, interleukin-1beta and angiotensin-converting enzyme, although with conflicting results; also cytochrome P450 drug-metabolising enzymes may bear a particular importance, although further corroboration of the findings is necessary, and further key participating genes remain to be identified. The hope is that the identification of these genetic components will eventually facilitate the development of a customised SSRI treatment.
Indexed as
Identifiers
15111987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.